Indian stock exchange

Proton Capital Enters Into Agreement to Purchase PharmaChoice Canada Branded Pharmacy In Saskatoon For Proposed Qualifying Transaction

Retrieved on: 
Thursday, February 22, 2024

The Share Purchase Agreement provides that Proton will purchase 75% of the issued and outstanding shares of the Target Pharmacy.

Key Points: 
  • The Share Purchase Agreement provides that Proton will purchase 75% of the issued and outstanding shares of the Target Pharmacy.
  • The Qualifying Transaction will not constitute a Non-Arm’s Length Qualifying Transaction (as such term is ‎defined in the policies of the TSXV).
  • The parties to the Qualifying Transaction are at arm’s length and therefore the approval of the shareholders of ‎Proton in respect of the Qualifying Transaction will not be required.
  • The Prospectus will contain important detailed information about the Corporation, the Qualifying ‎Transaction and the proposed Offering.

Timbercreek Financial Declares February 2024 Dividend

Retrieved on: 
Wednesday, February 21, 2024

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on March 15, 2024 to holders of Common Shares of record on February 29, 2024.

Key Points: 
  • TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on March 15, 2024 to holders of Common Shares of record on February 29, 2024.
  • The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees.
  • Common Shares acquired under the Plan will be automatically enrolled in the Plan.
  • Shareholders who hold their Common Shares through a broker, financial institution or other nominee must enroll for distribution reinvestment through their nominee holder.

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Retrieved on: 
Wednesday, February 21, 2024

For the fourth quarter of Fiscal 2023, sales of EGRIFTA SV® reached $16,958,000 compared to $14,458,000 in the fourth quarter of the prior year, representing an increase of 17.3%.

Key Points: 
  • For the fourth quarter of Fiscal 2023, sales of EGRIFTA SV® reached $16,958,000 compared to $14,458,000 in the fourth quarter of the prior year, representing an increase of 17.3%.
  • In the fourth quarter of Fiscal 2023, Trogarzo® sales amounted to $6,494,000 compared to $6,963,000 for the same quarter of Fiscal 2022, representing a decrease of 6.7%.
  • Lower unit sales in the fourth quarter of Fiscal 2023, were also a result of higher inventory buildup in Fiscal 2022, a situation which has resolved itself in Fiscal 2023.
  • Net finance costs in the fourth quarter of Fiscal 2022 included interest on the Convertible Notes, whereas this amount was nil in the fourth quarter of Fiscal 2023.

The Herzfeld Caribbean Basin Fund, Inc. Commences Tender Offer for up to 10% of Outstanding Common Shares

Retrieved on: 
Tuesday, February 20, 2024

MIAMI BEACH, Fla., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Thomas J. Herzfeld Advisors, Inc., an SEC-registered investment advisor, today announced the commencement of a Tender Offer by The Herzfeld Caribbean Basin Fund, Inc. (NASDAQ: CUBA) (the “Fund”).

Key Points: 
  • MIAMI BEACH, Fla., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Thomas J. Herzfeld Advisors, Inc., an SEC-registered investment advisor, today announced the commencement of a Tender Offer by The Herzfeld Caribbean Basin Fund, Inc. (NASDAQ: CUBA) (the “Fund”).
  • Under the terms of the Tender Offer the Fund is offering to purchase up to 10% of outstanding shares of the Fund at 97.5% of NAV.
  • Shareholders of the Fund should read the Offer to Purchase, the Letter of Transmittal and related exhibits, as they will contain important information about the Tender Offer.
  • Requests for more information, questions and requests for additional copies of the offer materials, please contact EQ Fund Solutions, LLC, the Information Agent for the Tender Offer, at (877) 291-1738.

Nevada Exploration Corporate Update

Retrieved on: 
Tuesday, February 20, 2024

VANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nevada Exploration Inc. (“NGE” or the “Company”) (TSX-V:NGE; OTCQB:NVDEF) announces the assays for drillhole SGVC014A at its South Grass Valley property, property acquisition negotiations, addition of directors, and a private placement financing.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nevada Exploration Inc. (“NGE” or the “Company”) (TSX-V:NGE; OTCQB:NVDEF) announces the assays for drillhole SGVC014A at its South Grass Valley property, property acquisition negotiations, addition of directors, and a private placement financing.
  • Sandra MacKay serves as the Global Vice President, Legal and Corporate Secretary, for Copperleaf Technologies Inc. She joined Copperleaf in 2022 and brings over 30 years of corporate-commercial legal experience to the company.
  • She has a wealth of legal experience in securities law, corporate governance, and intellectual property law matters as well as experience on a wide range of commercial transactions.
  • Mr. Hilditch is the President and owner of Rock Management Consulting Ltd., a private mining management services and consulting company.

Osino Resources Announces Receipt of Superior Acquisition Proposal

Retrieved on: 
Monday, February 19, 2024

Pursuant to the terms of the New Offer, the Company's shareholders would receive cash consideration of C$1.90 for each Common Share, valuing Osino at approximately C$368 million.

Key Points: 
  • Pursuant to the terms of the New Offer, the Company's shareholders would receive cash consideration of C$1.90 for each Common Share, valuing Osino at approximately C$368 million.
  • Following delivery of the notice, the Company received notice from DPM advising that DPM will not propose to amend the terms of the DPM Arrangement Agreement in light of the Superior Proposal.
  • Further details regarding the DPM Arrangement Agreement and the Superior Proposal will be provided once available in due course.
  • This news release does not constitute a change of recommendation regarding the offer by DPM under the DPM Arrangement Agreement.

Carbeeza Inc. Closes 2nd and 3rd Tranches Unit Private Placement

Retrieved on: 
Tuesday, March 5, 2024

is pleased to announce that it has closed its previously announced non-brokered private placement (the "Private Placement") of units of the Company ("Units”).

Key Points: 
  • is pleased to announce that it has closed its previously announced non-brokered private placement (the "Private Placement") of units of the Company ("Units”).
  • Pursuant to the closing of the 2nd and 3rd Tranche Private Placement, the Company issued 6,500,000 Units at a price of $0.10 per Unit for gross proceeds of $650,000.
  • The net proceeds of the Private Placement will be used by the Company to scale up the marketing campaign, to expedite the Company's move into the United States market and for general corporate purposes.
  • Using state-of-the-art technology, Carbeeza brings the process of buying a car right to the phone, tailor-made for the consumer.

Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program

Retrieved on: 
Thursday, February 29, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current Program.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current Program.
  • Aurinia announced on February 15th that its Board of Directors (the “Board”) had approved a share repurchase program (the “Current Program”) of up to $150 million common shares of the Company (each, a “Common Share”), affirming its confidence in the Company’s growth prospects.
  • The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws.
  • The exemptive relief is conditional upon, among other things, purchases being made in compliance with applicable U.S. securities laws, the Common Shares not being listed in Canada and the limits described herein.

NMG Announces the Successful Closing of the US$50 Million Tranche 1 Investment by GM and Panasonic

Retrieved on: 
Wednesday, February 28, 2024

Through the Tranche 1 Investment, each of GM and Panasonic subscribed for 12,500,000 Common Shares and 12,500,000 Warrants for an aggregate purchase price of US$25 million.

Key Points: 
  • Through the Tranche 1 Investment, each of GM and Panasonic subscribed for 12,500,000 Common Shares and 12,500,000 Warrants for an aggregate purchase price of US$25 million.
  • The Company intends to use the proceeds of the Tranche 1 Investment to support the advancement of NMG’s Phase-2 operations – the Matawinie Mine and the Bécancour Battery Material Plant – in line with their respective battery specifications.
  • The Warrants are subject to a hold period of 4 months and one day expiring on June 29, 2024.
  • Prior to the Tranche 1 Investment, Panasonic owned no shares in the capital of NMG and no Warrants.

Indiva Announces Filing of Amended and Restated Offering Document and Concurrent Private Placement of up to $4.3 Million

Retrieved on: 
Wednesday, February 28, 2024

The LIFE Offering pursuant to the Amended and Restated Offering Document will consist of up to 40,000,000 units of the Company (each, a "LIFE Unit") for aggregate gross proceeds to the Company of up to $4,000,000.

Key Points: 
  • The LIFE Offering pursuant to the Amended and Restated Offering Document will consist of up to 40,000,000 units of the Company (each, a "LIFE Unit") for aggregate gross proceeds to the Company of up to $4,000,000.
  • The Amended and Restated Offering Document relating to the LIFE Offering can be accessed under the Company's profile at www.sedarplus.ca and at www.indiva.com .
  • Prospective investors should read the Amended and Restated Offering Document before making an investment decision.
  • Upon closing of the Concurrent Offering, the Company may pay certain eligible finders a finder's fee of up to $400,000.